TNONHealthcare · Medical Devices

TNON Stock Forecast: TENON Medical, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026

$2.05

The 2 Wall Street analysts covering TENON Medical, Inc. hold a median 12-month price target of $11 — +412.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 31 Oct 2026 — in the upper half.

Market cap

$5.5M

Ticker Nerd rank

51/ 100

Median analyst target

$11

Analysts covering

Revenue$1.3M+126.8% y/y

Operating income−$3.4M

Net income−$4.0M

Free cash flow−$2.9M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Ticker Nerd rank

TNON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TENON Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026

51/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Revisions

Volatility

Accruals

Quality

Momentum

Value

Issuance

Size (94): Smaller than most of the companies we track.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TNON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNON, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $10Median $11High $11

The green dot is the last close — the median target sits +412.2% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
9 Apr 2025	Alliance Global Partners	Initiates	Buy	$3.00
15 Nov 2024	Maxim Group	Maintains	Buy	—
14 Aug 2024	Benchmark	Reiterates	Speculative Buy	—
15 Apr 2024	Benchmark	Maintains	Speculative Buy	—
10 Mar 2023	Benchmark	Reiterates	Buy	$6.00
6 Sept 2022	Benchmark	Initiates	Speculative Buy	—
21 June 2022	Benchmark	Initiates	Speculative Buy	$6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TNON appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Estimates

TNON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

TENON Medical, Inc. (TNON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.1×
Price / sales: 1.0×
Price / book: −0.4×
EV / EBITDA: −0.7×

Growth & margins

Revenue growth (YoY): 126.8%
Earnings growth (YoY): 126.8%
Gross margin: 63.6%
Operating margin: −262.2%
Net margin: −257.9%

Returns & dividend

Return on equity: −551.2%
Return on assets: −72.0%
Dividend yield: 34.6%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TENON Medical, Inc. (TNON) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

TENON Medical, Inc. has a market value of $5.5M and an enterprise value of $8.4M.
Revenue in the twelve months to 30 June 2026: $5.3M. The latest quarter grew 126.8% year on year.
Net income over the same four quarters: −$13.7M, a −257.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$12.1M.
Shares outstanding: 496,456.
Trailing P/E: 0.1×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 34.63%, paying out 0% of earnings.
TENON Medical, Inc. employs 26 people — $204K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

TNON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
TNONTENON Medical, Inc.	$5.5M	51
VNRXVolitionRX Ltd.	$5.4M	43
INBSIntelligent Bio Solutions, Inc.	$5.8M	16
BDMDBaird Medical Investment Holdings Ltd.	$5.1M	49
NVNOenVVeno Medical Corp.	$4.7M	28
WOKWORK Medical Technology Group Ltd.	$4.5M	17
BMRABiomerica, Inc.	$7.9M	14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TENON Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TNON news & analysis

Tenon Medical(R) Adds Eight New Patents Issued by the United States Patent and Trademark Office Through Q3 2026

Accesswire · 15 Oct 2026positive

Tenon Medical announced that the USPTO has issued eight new patents to the company so far in fiscal 2026. Its portfolio now includes 38 issued U.S. patents, 9 international patents, and 31 pending U.S. and foreign applications.

Why it matters — The announcement updates TNON watchers on the size of the company's intellectual-property portfolio and its pending applications.

Tenon(R) Medical Announces Full Commercial Launch of the SImmetry(R)+ SI Joint Fusion 3D Printed Lateral Screw Following Successful Alpha Launch

Accesswire · 30 Sept 2026positive

Tenon Medical announced the full commercial launch of its titanium 3D-printed lateral screw as part of the SImmetry+ SI Joint Fusion System, following a successful Alpha launch that generated approximately $1.2 million in incremental revenue from late Q4 2025 through Q3 2026. The company plans to expand instrument set inventory to support anticipated demand, describing the screw as the first component of a next-generation lateral SI joint fusion system.

Why it matters — This marks a commercial milestone and generates early revenue validation for Tenon's next-generation SImmetry+ system, which is expected to be followed by several additional product launches in coming quarters.

WallachBeth Capital Announces Closing of Tenon Medical Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338

PRNewsWire · 14 Sept 2026neutral

WallachBeth Capital announced the closing of Tenon Medical's warrant inducement offering, in which an institutional investor exercised outstanding warrants to purchase an aggregate of 572,179 shares of common stock. The offering generated approximately $2,872,338 in aggregate gross proceeds.

Why it matters — TNON watchers would care because this transaction brings in new capital for the company through exercised warrants, affecting the company's share structure and financial position.

Tenon Medical Announces Closing of Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338

Accesswire · 14 Sept 2026neutral

Tenon Medical announced it closed a warrant inducement agreement with an institutional investor, who exercised outstanding warrants to purchase 572,179 shares of common stock for gross cash proceeds of approximately $2,872,338. In exchange for the immediate exercise, the holder received new unregistered warrants to purchase up to 858,269 shares at an exercise price of $5.02 per share.

Why it matters — The closing of this warrant exercise provides the company with additional gross proceeds while also issuing new warrants, which could result in future dilution for existing shareholders.

WallachBeth Capital Announces Tenon Medical Warrant Inducement for Gross Proceeds of Approximately $2,872,338

PRNewsWire · 11 Sept 2026positive

WallachBeth Capital announced that Tenon Medical entered into warrant exercise agreements with an institutional investor to exercise outstanding warrants for 572,179 shares of common stock, generating gross proceeds of approximately $2,872,338.

Why it matters — This warrant exercise brings fresh capital of roughly $2.9 million to Tenon Medical, providing additional funding for the company.

FAQ

Frequently asked questions about TNON stock

What is the TNON stock price forecast for 2026-2027?

The 2 Wall Street analysts covering TENON Medical, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNON stock a buy right now?

Of the 2 analysts covering TENON Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TENON Medical, Inc. 51 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNON?

As at 31 Oct 2026, TENON Medical, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will TNON stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +412.2% from the last close, and Ticker Nerd's factor model ranks TENON Medical, Inc. 51 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNON stock forecast for 2030?

No analyst covering TENON Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $11 over the next 12 months.

What does TENON Medical, Inc. do?

Tenon Medical, Inc. is a medical device company focused on minimally invasive solutions for sacroiliac joint disorders and severe lower back pain.

What is the latest news on TNON?

The most recent item we track (Accesswire, 15 Oct 2026): "Tenon Medical(R) Adds Eight New Patents Issued by the United States Patent and Trademark Office Through Q3 2026". Tenon Medical announced that the USPTO has issued eight new patents to the company so far in fiscal 2026. Its portfolio now includes 38 issued U.S. patents, 9 international patents, and 31 pending U.S. and foreign applications.

Company

About TENON Medical, Inc.

Tenon Medical, Inc. is a medical device company focused on minimally invasive solutions for sacroiliac joint disorders and severe lower back pain. Tenon Medical develops and commercializes the Catamaran SI Joint Fusion System, along with related fixation technology, designed to stabilize and fuse the sacroiliac joint through an inferior-posterior approach using a titanium implant. Its products are used in primary SI joint procedures, revision procedures involving failed implants, and adjunct applications alongside spine fusion constructs. Based in Los Gatos, California, Tenon Medical serves the surgical spine and orthopedics market with implant systems aimed at addressing SI joint dysfunction and sacro-pelvic instability.

CEO Mr. Steven M. Foster · 26 employees · United States · https://www.tenonmed.com